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Background: Prospective randomized trials have demonstrated the 1-year superiority of the 2nd generation everolimus-eluting stent (EES) as 
compared to paclitaxel-eluting stent (PES) in safety and efficacy endpoints. However, these trials were underpowered for low frequency safety 
endpoints, and whether this relative benefit of EES (versus PES) is durable or erodes over time beyond 1 year has not been determined.
Methods: We therefore analysed a 6,788 patient-level pooled database from four EES versus PES randomised trials: SPIRIT II, III, IV and COMPARE. 
Kaplan-Meier estimates of clinical outcomes were assessed at 2-years as well as between 1 and 2 years and compared with the log-rank test.
Results: Event rates at 2 years and between 1 and 2 years are shown in the table. At 2 years EES results in a significant improvement in all MI, 
Q-wave MI, and ischemic TLR. MI, Q-wave MI and stent thrombosis rates were further reduced between 1 and 2 years with EES compared to PES, with 
no significant differences in the rates of TLR or TVR present after 1 year between the stent types.
Conclusion: The 2 year follow-up in 6,788 pts from 4 randomized trials unequivocally demonstrates that the 2nd generation EES markedly 
improves event-free survival compared to PES, with improved safety and efficacy. Notably, after 1 year follow-up, fewer MIs, Q-wave MIs and stent 
thrombosis accrue in patients treated with EES. 
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XIENCE TAXUS
Hazard Ratio
[95% C.I.]
P-Value XIENCE TAXUS
Hazard Ratio
[95% C.I.]
P-Value
Death 2.5% (101) 3.0% (73) 0.82 [0.61,1.11] 0.20 1.2% (49) 1.7% (38) 0.76 [0.50,1.17] 0.21
Cardiac 1.2% (49) 1.5% (37) 0.79 [0.51,1.21] 0.28 0.6% (23) 0.8% (18) 0.76 [0.41,1.40] 0.38
MI 2.9% (122) 5.5% (137) 0.53 [0.41,0.67] <.0001 0.8% (32) 1.6% (36) 0.52 [0.32,0.83] 0.006
Q-Wave 0.2% (9) 1.2% (28) 0.19 [0.09,0.40] <.0001 0.0% (1) 0.5% (11) 0.05 [0.01,0.41] <.0001
Ischemic TLR 4.1% (167) 6.6% (162) 0.60 [0.48,0.75] <.0001 1.8% (69) 2.0% (44) 0.90 [0.62,1.32] 0.61
Stent Thrombosis 
(def/prob)
0.7% (28) 2.3% (56) 0.30 [0.19,0.47] <.0001 0.3% (10) 0.8% (19) 0.31 [0.14,0.67] 0.002
Death/MI 5.2% (215) 8.0% (198) 0.64 [0.53,0.77] <.0001 2.0% (78) 3.0% (68) 0.67 [0.48,0.92] 0.01
Death/MI/TLR 8.9% (367) 13.2% (324) 0.66 [0.56,0.76] <.0001 3.7% (140) 4.5% (95) 0.84 [0.65,1.09] 0.18
